The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
5 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,270,727 in first-year total cost, median $400,000.
Most frequent study sections
- Special Emphasis Panel[ZDA1 SUY-S (J1)]3
- Special Emphasis Panel[ZDA1 SUY-S (A1)]2
Most frequent institutions
- GENERAL BIOPHYSICS, LLC1
- PHOTOPHARMICS, INC.1
- RAFIAS LLC1
- SYNCANICA BIO1
- VERISIM LIFE, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Development of therapeutic candidates for stimulant use disorder using AI-driven platform for focused drug discovery and accelerated development2R42DA056084-02 | MILLER, COURTNEY AVARSHNEY, JYOTIKA | VERISIM LIFE, INC., CA | $811,876 | ZDA1 |
| 2025 | Advancing Nr4a1 as a novel target in cocaine use disorder.1R41DA061874-01 | HELLER, ELIZABETH A | RAFIAS LLC, PA | $405,230 | ZDA1 |
| 2025 | Xenon gas inhalation as a novel treatment for opioid withdrawal syndrome1R41DA061962-01 | ILIN, ILYA | GENERAL BIOPHYSICS, LLC, MA | $400,000 | ZDA1 |
| 2025 | Pseudocannabinoids for mitigation of substance use disorder1R41DA061907-01A1 | MASCAL, MARK | SYNCANICA BIO, CA | $334,343 | ZDA1 |
| 2024 | Amelioration of opioid use disorder with heterodyned whole body vibration1R42DA060644-01 | ADAMS, DANIEL NATHANSTEFFENSEN, SCOTT C | PHOTOPHARMICS, INC., UT | $319,278 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.